id_top,topic,keyword,number,normal,max
t0,Molecular typing,strains,56,100,56
t0,Molecular typing,epidemiology,41,73,56
t0,Molecular typing,molecular epidemiology,27,48,56
t0,Molecular typing,genetic diversity,24,42,56
t0,Molecular typing,mutations,21,37,56
t0,Molecular typing,transmission,20,35,56
t0,Molecular typing,beijing genotype,20,35,56
t0,Molecular typing,spread,17,30,56
t0,Molecular typing,pulmonary tb,14,25,56
t0,Molecular typing,identification,13,23,56
t0,Molecular typing,complex,13,23,56
t0,Molecular typing,population,12,21,56
t0,Molecular typing,family,12,21,56
t0,Molecular typing,database,12,21,56
t0,Molecular typing,drug-resistant tb,11,19,56
t0,Molecular typing,susceptibility,11,19,56
t0,Molecular typing,drug-resistance,10,17,56
t0,Molecular typing,polymorphism,10,17,56
t0,Molecular typing,genotype,10,17,56
t0,Molecular typing,prevalence,10,17,56
t1,Drug-related research,mutations,127,100,127
t1,Drug-related research,strains,126,99,127
t1,Drug-related research,drug-resistance,104,81,127
t1,Drug-related research,gene,69,54,127
t1,Drug-related research,susceptibility,62,48,127
t1,Drug-related research,rifampicin,57,44,127
t1,Drug-related research,drugs,57,44,127
t1,Drug-related research,rpob,55,43,127
t1,Drug-related research,pulmonary tb,54,42,127
t1,Drug-related research,rifampicin resistance,53,41,127
t1,Drug-related research,epidemiology,44,34,127
t1,Drug-related research,isoniazid resistance,43,33,127
t1,Drug-related research,anti-tb,40,31,127
t1,Drug-related research,rapid detection,40,31,127
t1,Drug-related research,identification,40,31,127
t1,Drug-related research,complex,38,29,127
t1,Drug-related research,agents,35,27,127
t1,Drug-related research,assay,34,26,127
t1,Drug-related research,multidrug-resistant,34,26,127
t1,Drug-related research,transmission,33,25,127
t2,Operational research,pulmonary tb,90,100,90
t2,Operational research,drug-resistance,49,54,90
t2,Operational research,south-africa,46,51,90
t2,Operational research,treatment outcomes,37,41,90
t2,Operational research,infection,35,38,90
t2,Operational research,multidrug-resistant,35,38,90
t2,Operational research,transmission,33,36,90
t2,Operational research,metaanalysis,33,36,90
t2,Operational research,drug-resistant tb,33,36,90
t2,Operational research,therapy,31,34,90
t2,Operational research,epidemiology,29,32,90
t2,Operational research,hiv,28,31,90
t2,Operational research,risk-factors,26,28,90
t2,Operational research,diagnosis,25,27,90
t2,Operational research,anti-tb,25,27,90
t2,Operational research,prevalence,25,27,90
t2,Operational research,care,24,26,90
t2,Operational research,xdr-tb,23,25,90
t2,Operational research,short-course chemotherapy,22,24,90
t2,Operational research,health,21,23,90
t3,Diagnostics,mutations,71,100,71
t3,Diagnostics,diagnosis,60,84,71
t3,Diagnostics,rifampicin resistance,57,80,71
t3,Diagnostics,drug-resistance,56,78,71
t3,Diagnostics,rapid detection,49,69,71
t3,Diagnostics,rifampicin,46,64,71
t3,Diagnostics,strains,44,61,71
t3,Diagnostics,rpob,41,57,71
t3,Diagnostics,assay,36,50,71
t3,Diagnostics,line probe assay,35,49,71
t3,Diagnostics,pulmonary tb,34,47,71
t3,Diagnostics,gene,32,45,71
t3,Diagnostics,isoniazid resistance,30,42,71
t3,Diagnostics,south-africa,27,38,71
t3,Diagnostics,susceptibility,25,35,71
t3,Diagnostics,metaanalysis,22,30,71
t3,Diagnostics,clinical specimens,22,30,71
t3,Diagnostics,specimens,21,29,71
t3,Diagnostics,pcr,21,29,71
t3,Diagnostics,prevalence,19,26,71
t5,Treatment optimization,pulmonary tb,204,100,204
t5,Treatment optimization,drug-resistance,119,58,204
t5,Treatment optimization,therapy,99,48,204
t5,Treatment optimization,treatment outcomes,99,48,204
t5,Treatment optimization,metaanalysis,95,46,204
t5,Treatment optimization,risk-factors,95,46,204
t5,Treatment optimization,prevalence,76,37,204
t5,Treatment optimization,south-africa,75,36,204
t5,Treatment optimization,epidemiology,73,35,204
t5,Treatment optimization,infection,67,32,204
t5,Treatment optimization,transmission,66,32,204
t5,Treatment optimization,management,64,31,204
t5,Treatment optimization,outcomes,56,27,204
t5,Treatment optimization,drugs,55,26,204
t5,Treatment optimization,rifampicin,54,26,204
t5,Treatment optimization,impact,53,25,204
t5,Treatment optimization,surveillance,52,25,204
t5,Treatment optimization,multidrug-resistant,51,25,204
t5,Treatment optimization,diagnosis,48,23,204
t5,Treatment optimization,peru,46,22,204
t6,Immunology,pulmonary tb,24,100,24
t6,Immunology,infection,23,95,24
t6,Immunology,disease,10,41,24
t6,Immunology,therapy,9,37,24
t6,Immunology,interferon-gamma,9,37,24
t6,Immunology,ifn-gamma,9,37,24
t6,Immunology,responses,9,37,24
t6,Immunology,immune-responses,9,37,24
t6,Immunology,delivery,8,33,24
t6,Immunology,active tb,7,29,24
t6,Immunology,expression,7,29,24
t6,Immunology,cytokines,7,29,24
t6,Immunology,antigens,7,29,24
t6,Immunology,lymphocytes,7,29,24
t6,Immunology,drugs,7,29,24
t6,Immunology,mice,6,25,24
t6,Immunology,cells,6,25,24
t6,Immunology,growth-factor-beta,5,20,24
t6,Immunology,blood mononuclear-cells,5,20,24
t6,Immunology,chemotherapy,5,20,24
t1_s0,Resistance genes,strains,32,100,32
t1_s0,Resistance genes,mutations,29,90,32
t1_s0,Resistance genes,drug-resistance,26,81,32
t1_s0,Resistance genes,gene,25,78,32
t1_s0,Resistance genes,rifampicin,19,59,32
t1_s0,Resistance genes,isoniazid resistance,14,43,32
t1_s0,Resistance genes,rpob,14,43,32
t1_s0,Resistance genes,rifampicin resistance,14,43,32
t1_s0,Resistance genes,susceptibility,12,37,32
t1_s0,Resistance genes,pcr,11,34,32
t1_s0,Resistance genes,complex,10,31,32
t1_s0,Resistance genes,rapid detection,9,28,32
t1_s0,Resistance genes,molecular characterization,8,25,32
t1_s0,Resistance genes,identification,8,25,32
t1_s0,Resistance genes,ethambutol resistance,8,25,32
t1_s0,Resistance genes,china,8,25,32
t1_s0,Resistance genes,inha,7,21,32
t1_s0,Resistance genes,molecular analysis,7,21,32
t1_s0,Resistance genes,katg,7,21,32
t1_s0,Resistance genes,assay,7,21,32
t1_s2,Plant extracts,derivatives,4,100,4
t1_s2,Plant extracts,natural-products,4,100,4
t1_s2,Plant extracts,assay,3,75,4
t1_s2,Plant extracts,drugs,3,75,4
t1_s2,Plant extracts,strains,3,75,4
t1_s2,Plant extracts,resistant,3,75,4
t1_s2,Plant extracts,rifampicin,3,75,4
t1_s2,Plant extracts,antibacterial,3,75,4
t1_s2,Plant extracts,inhibition,3,75,4
t1_s2,Plant extracts,antibacterial activity,2,50,4
t1_s2,Plant extracts,mutations,2,50,4
t1_s2,Plant extracts,complex,2,50,4
t1_s2,Plant extracts,in-vitro,2,50,4
t1_s2,Plant extracts,plants,2,50,4
t1_s2,Plant extracts,h37rv,2,50,4
t1_s2,Plant extracts,discovery,2,50,4
t1_s2,Plant extracts,drug-resistance,2,50,4
t1_s2,Plant extracts,docking,2,50,4
t1_s2,Plant extracts,target,2,50,4
t1_s2,Plant extracts,cell-cultures,1,25,4
t1_s5,2nd line regimens,drug-resistance,14,100,14
t1_s5,2nd line regimens,mutations,14,100,14
t1_s5,2nd line regimens,strains,11,78,14
t1_s5,2nd line regimens,gene,11,78,14
t1_s5,2nd line regimens,anti-tb,10,71,14
t1_s5,2nd line regimens,agents,10,71,14
t1_s5,2nd line regimens,drugs,9,64,14
t1_s5,2nd line regimens,in-vitro,9,64,14
t1_s5,2nd line regimens,mechanisms,9,64,14
t1_s5,2nd line regimens,susceptibility,9,64,14
t1_s5,2nd line regimens,smegmatis,7,50,14
t1_s5,2nd line regimens,china,7,50,14
t1_s5,2nd line regimens,rifampicin,6,42,14
t1_s5,2nd line regimens,resistant,6,42,14
t1_s5,2nd line regimens,protein,6,42,14
t1_s5,2nd line regimens,binding,5,35,14
t1_s5,2nd line regimens,drug-resistant tb,5,35,14
t1_s5,2nd line regimens,escherichia-coli,5,35,14
t1_s5,2nd line regimens,identification,5,35,14
t1_s5,2nd line regimens,multidrug-resistant,5,35,14
t1_s6,New compounds,derivatives,22,100,22
t1_s6,New compounds,agents,20,90,22
t1_s6,New compounds,activity,14,63,22
t1_s6,New compounds,anti-tb,13,59,22
t1_s6,New compounds,inhibitors,13,59,22
t1_s6,New compounds,discovery,13,59,22
t1_s6,New compounds,drugs,12,54,22
t1_s6,New compounds,dna gyrase,11,50,22
t1_s6,New compounds,antimycobacterial,9,40,22
t1_s6,New compounds,analogs,8,36,22
t1_s6,New compounds,design,8,36,22
t1_s6,New compounds,target,7,31,22
t1_s6,New compounds,crystal-structure,6,27,22
t1_s6,New compounds,in-vitro,6,27,22
t1_s6,New compounds,acid,5,22,22
t1_s6,New compounds,drug-resistance,5,22,22
t1_s6,New compounds,ciprofloxacin,5,22,22
t1_s6,New compounds,infection,5,22,22
t1_s6,New compounds,mechanisms,5,22,22
t1_s6,New compounds,potent,5,22,22
t5_s2,Treatment regimens,therapy,31,100,31
t5_s2,Treatment regimens,pulmonary tb,30,96,31
t5_s2,Treatment regimens,treatment outcomes,24,77,31
t5_s2,Treatment regimens,metaanalysis,23,74,31
t5_s2,Treatment regimens,drug-resistance,19,61,31
t5_s2,Treatment regimens,management,16,51,31
t5_s2,Treatment regimens,peru,15,48,31
t5_s2,Treatment regimens,drugs,15,48,31
t5_s2,Treatment regimens,outcomes,14,45,31
t5_s2,Treatment regimens,efficacy,14,45,31
t5_s2,Treatment regimens,short-course chemotherapy,13,41,31
t5_s2,Treatment regimens,rifampicin,13,41,31
t5_s2,Treatment regimens,chemotherapy,11,35,31
t5_s2,Treatment regimens,cohort,11,35,31
t5_s2,Treatment regimens,tolerability,10,32,31
t5_s2,Treatment regimens,regimens,10,32,31
t5_s2,Treatment regimens,risk-factors,10,32,31
t5_s2,Treatment regimens,south-africa,9,29,31
t5_s2,Treatment regimens,impact,8,25,31
t5_s2,Treatment regimens,xdr-tb,8,25,31
t5_s3,Risk factors,risk-factors,23,100,23
t5_s3,Risk factors,pulmonary tb,21,91,23
t5_s3,Risk factors,drug-resistance,16,69,23
t5_s3,Risk factors,treatment outcomes,16,69,23
t5_s3,Risk factors,therapy,14,60,23
t5_s3,Risk factors,metaanalysis,14,60,23
t5_s3,Risk factors,south-africa,13,56,23
t5_s3,Risk factors,impact,12,52,23
t5_s3,Risk factors,predictors,10,43,23
t5_s3,Risk factors,cohort,10,43,23
t5_s3,Risk factors,epidemiology,10,43,23
t5_s3,Risk factors,hiv-infection,9,39,23
t5_s3,Risk factors,mortality,9,39,23
t5_s3,Risk factors,default,8,34,23
t5_s3,Risk factors,surveillance,8,34,23
t5_s3,Risk factors,transmission,7,30,23
t5_s3,Risk factors,drugs,7,30,23
t5_s3,Risk factors,anti-tb,7,30,23
t5_s3,Risk factors,prevalence,7,30,23
t5_s3,Risk factors,hiv,7,30,23
t5_s5,Resistance prevalence,pulmonary tb,9,100,9
t5_s5,Resistance prevalence,drug-resistance,9,100,9
t5_s5,Resistance prevalence,prevalence,9,100,9
t5_s5,Resistance prevalence,outcomes,7,77,9
t5_s5,Resistance prevalence,risk-factors,7,77,9
t5_s5,Resistance prevalence,infection,6,66,9
t5_s5,Resistance prevalence,impact,5,55,9
t5_s5,Resistance prevalence,epidemiology,5,55,9
t5_s5,Resistance prevalence,anti-tb,4,44,9
t5_s5,Resistance prevalence,new-york,4,44,9
t5_s5,Resistance prevalence,mellitus,3,33,9
t5_s5,Resistance prevalence,surveillance,3,33,9
t5_s5,Resistance prevalence,prison,3,33,9
t5_s5,Resistance prevalence,europe,3,33,9
t5_s5,Resistance prevalence,russia,3,33,9
t5_s5,Resistance prevalence,countries,3,33,9
t5_s5,Resistance prevalence,multidrug-resistant,3,33,9
t5_s5,Resistance prevalence,transmission,3,33,9
t5_s5,Resistance prevalence,hiv-infection,3,33,9
t5_s5,Resistance prevalence,rifampicin,3,33,9
